RegeneRx Biopharmaceuticals has been issued a notice of allowance by the U.S. Patent and Trademark Office for a new patent for treating corneal wounds using thymosin beta 4 or related therapeutic peptides, according to a press release.
Thymosin beta 4 (Tβ4) is the active ingredient in the company’s drug candidate, RGN-259, a preservative-free eye drop for patients with corneal wounds.
RGN-259 is currently in phase 3 clinical trials in the United States, where RegeneRx has licensed its rights to ReGenTree LLC.
“We believe this patent will complement our recently issued dry eye
Uncategorized